Prothena Corporation PLC
PRTA
查看詳細走勢圖
9.540USD
-0.150-1.55%
收盤 12/26, 16:00（美東）報價延遲15分鐘
513.54M總市值
虧損本益比TTM
盤中分時
1分
30分
1小時
日k
週k
月k
日k
今天
-1.55%
5天
+3.58%
1月
-8.53%
6月
+56.91%
今年開始到現在
-31.12%
1年
-36.99%
查看詳細走勢圖
TradingKey Prothena Corporation PLC股票評分
單位: USD 更新時間: 2025-12-26操作建議
Prothena Corporation PLC當前公司基本面數據相對非常健康，增長潛力較大。當前估值合理，在生物技術與醫療研究行業排名131/404位。機構持股佔比非常高，近一個月多位分析師給出公司評級為持有。最高目標價20.33。中期看，股價處於平穩狀態。近一個月，市場表現較差，但基本面評分較高。目前股價在壓力位和支撐位之間，可以做區間波段操作。
Prothena Corporation PLC評分
壓力支撐
由於公司未披露，未能獲取相關數據
多維評測
本期評分
上期評分
分析師目標
基於
7
分析師
持有
評級
20.333
目標均價
+89.50%
漲幅空間
數據免責聲明：分析師評級與目標價由LSEG提供，僅供參考，不應當作投資建議
Prothena Corporation PLC亮點
亮點風險
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
業績高增長
公司營業收入穩步增長，連續3年增長150.73%
估值高估
公司最新PE估值-1.83，處於3年歷史高位
機構減倉
最新機構持股41.85M股，環比減少26.64%
CI 精選加拿大股票基金持倉
明星投資者CI 精選加拿大股票基金持倉，最新持倉3.67K股
Prothena Corporation PLC新聞
即將為您帶來更多新聞，敬請期待。 。 。
財務指標
每股收益
由於公司未披露，未能獲取相關數據
營業總收入
由於公司未披露，未能獲取相關數據
Prothena Corporation PLC簡介
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
公司代碼PRTA
公司Prothena Corporation PLC
CEOKinney (Gene G)
網址https://www.prothena.com/
常見問題
Prothena Corporation PLC(PRTA)的當前股價是多少？
Prothena Corporation PLC(PRTA)的當前股價是 9.540。
Prothena Corporation PLC 的股票代碼是什麼？
Prothena Corporation PLC的股票代碼是PRTA。
Prothena Corporation PLC股票的52週最高點是多少？
Prothena Corporation PLC股票的52週最高點是16.665。
Prothena Corporation PLC股票的52週最低點是多少？
Prothena Corporation PLC股票的52週最低點是4.320。
Prothena Corporation PLC的市值是多少？
Prothena Corporation PLC的市值是513.54M。
Prothena Corporation PLC的淨利潤是多少？
Prothena Corporation PLC的淨利潤為-122.31M。
現在Prothena Corporation PLC(PRTA)的股票是買入、持有還是賣出？
根據分析師評級，Prothena Corporation PLC(PRTA)的總體評級為持有，目標價格為20.333。
Prothena Corporation PLC(PRTA)股票的每股收益（EPS TTM）是多少
Prothena Corporation PLC(PRTA)股票的每股收益（EPS TTM）是-5.211。
相關品種
+0.05%
-0.07%
+0.08%
+0.49%
+0.23%
+0.38%
-0.31%
-0.30%
-0.77%
+0.30%
+0.23%
-0.02%
-0.07%
+0.24%
+0.26%
+0.30%
+0.16%
0.00%
+0.58%
-0.02%
